Genetic events in the pathogenesis of multiple myeloma

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 4, 2007, Pages 571-596

  Chng, W J ^a   Glebov, O ^b   Bergsagel, P L ^a   Kuehl, W M ^b  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

gene expression profiling; genetics; hyperdiploid; IgH translocations; molecular pathogenesis; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; CD40 ANTIGEN; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN MDM2; PROTEIN P16; PROTEIN P18; PROTEIN P53; RETINOBLASTOMA PROTEIN; SCATTER FACTOR; SOMATOMEDIN C; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; SYNDECAN 1; TRANSCRIPTION FACTOR C MAF; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNINDEXED DRUG;

AMYLOIDOSIS; B LYMPHOCYTE; CANCER CLASSIFICATION; CANCER GENETICS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 13; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC RECOMBINATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VDJ EXON;

GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; KARYOTYPING; MULTIPLE MYELOMA; NF-KAPPA B; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 36749027626     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.08.004     Document Type: Review

References (108)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians 57 (2007) 43-66
2. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine 354 (2006) 1362-1369
3. Landgren O., Gridley G., Turesson I., et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107 (2006) 904-906
4. Lynch H.T., Watson P., Tarantolo S., et al. Phenotypic heterogeneity in multiple myeloma families. Journal of Clinical Oncology 23 (2005) 685-693
5. Shapiro-Shelef M., and Calame K. Regulation of plasma-cell development. Nature Reviews. Immunology 5 (2005) 230-242
6. Kuehl W.M., and Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nature Reviews. Cancer 2 (2002) 175-187
7. Rajkumar S.V., Fonseca R., Dewald G.W., et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genetics and Cytogenetics 113 (1999) 73-77
8. Salmon S.E. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Seminars in Hematology 10 (1973) 135-144
9. Katzmann J.A., Abraham R.S., Dispenzieri A., et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clinical Chemistry 51 (2005) 878-881
10. Bradwell A.R., Carr-Smith H.D., Mead G.P., et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 361 (2003) 489-491
11. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology 121 (2003) 749-757
12. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. The New England Journal of Medicine 346 (2002) 564-569
13. Rajkumar S.V., Kyle R.A., Therneau T.M., et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106 (2005) 812-817
14. Zhan F., Barlogie B., Arzoumanian V., et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109 (2007) 1692-1700
15. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews. Cancer 5 (2005) 251-262
16. Bergsagel P.L., and Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene 20 (2001) 5611-5622
17. Pasqualucci L., Neumeister P., Goossens T., et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412 (2001) 341-346
18. Fonseca R., Bailey R.J., Ahmann G.J., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100 (2002) 1417-1424
19. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101 (2003) 4569-4575
20. Avet-Loiseau H., Daviet A., Brigaudeau C., et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 97 (2001) 822-825
21. Avet-Loiseau H., Facon T., Grosbois B., et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99 (2002) 2185-2191
22. Hanamura I., Iida S., Ueda R., et al. Identification of three novel chromosomal translocation partners involving the immunoglobulin loci in newly diagnosed myeloma and human myeloma cell lines. Blood 106 (2005) [abstract 1552]
23. Chesi M., Bergsagel P.L., Brents L.A., et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88 (1996) 674-681
24. Chesi M., Bergsagel P.L., Shonukan O.O., et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91 (1998) 4457-4463
25. Chesi M., Nardini E., Brents L.A., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics 16 (1997) 260-264
26. Chesi M., Nardini E., Lim R.S., et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92 (1998) 3025-3034
27. Shaughnessy Jr. J., Gabrea A., Qi Y., et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98 (2001) 217-223
28. Hanamura I., Iida S., Akano Y., et al. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Japanese Journal of Cancer Research 92 (2001) 638-644
29. Chesi M., Brents L.A., Ely S.A., et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97 (2001) 729-736
30. Hurt E.M., Wiestner A., Rosenwald A., et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5 (2004) 191-199
31. Gabrea A., Leif Bergsagel P., and Michael Kuehl W. Distinguishing primary and secondary translocations in multiple myeloma. DNA Repair (Amst) 5 (2006) 1225-1233
32. Avet-Loiseau H., Facon T., Daviet A., et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Research 59 (1999) 4546-4550
33. Fonseca R., Blood E.A., Oken M.M., et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99 (2002) 3735-3741
34. Hayman S.R., Bailey R.J., Jalal S.M., et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 98 (2001) 2266-2268
35. Bergsagel P.L., Kuehl W.M., Zhan F., et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106 (2005) 296-303
36. Suzuki A., Iida S., Kato-Uranishi M., et al. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 24 (2005) 6936-6944
37. Keats J.J., Reiman T., Maxwell C.A., et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101 (2003) 1520-1529
38. Santra M., Zhan F., Tian E., et al. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101 (2003) 2374-2376
39. Keats J.J., Maxwell C.A., Taylor B.J., et al. Overexpression of transcripts originating from the MMSET Locus characterizes all t(4;14)(p16;q32) positive multiple myeloma patients. Blood 105 (2005) 4060-4069
40. Avet-Loiseau H., Gerson F., Magrangeas F., et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98 (2001) 3082-3086
41. Shou Y., Martelli M.L., Gabrea A., et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 228-233
42. Zhan F., Huang Y., Colla S., et al. The molecular classification of multiple myeloma. Blood 108 (2006) 2020-2028
43. Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109 (2007) 3489-3495
44. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research 64 (2004) 1546-1558
45. Sawyer J.R., Lukacs J.L., Munshi N., et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92 (1998) 4269-4278
46. Sawyer J.R., Lukacs J.L., Thomas E.L., et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. British Journal of Haematology 112 (2001) 167-174
47. Fonseca R., Debes-Marun C.S., Picken E.B., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102 (2003) 2562-2567
48. Bergsagel P.L., and Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology 23 (2005) 6333-6338
49. Smadja N.V., Fruchart C., Isnard F., et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 12 (1998) 960-969
50. Smadja N.V., Leroux D., Soulier J., et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes, Chromosomes & Cancer 38 (2003) 234-239
51. Facon T., Avet-Loiseau H., Guillerm G., et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97 (2001) 1566-1571
52. Fonseca R., Harrington D., Oken M.M., et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Research 62 (2002) 715-720
53. Zojer N., Konigsberg R., Ackermann J., et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95 (2000) 1925-1930
54. Konigsberg R., Ackermann J., Kaufmann H., et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 14 (2000) 1975-1979
55. Avet-Louseau H., Daviet A., Sauner S., et al. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. British Journal of Haematology 111 (2000) 1116-1117
56. Fonseca R., Oken M.M., Harrington D., et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 15 (2001) 981-986
57. Dewald G.W., Kyle R.A., Hicks G.A., et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66 (1985) 380-390
58. Sawyer J.R., Waldron J.A., Jagannath S., et al. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics 82 (1995) 41-49
59. Shaughnessy J., Tian E., Sawyer J., et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96 (2000) 1505-1511
60. Fonseca R., Oken M.M., and Greipp P.R. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 98 (2001) 1271-1272
61. Baker G.L., Landis M.W., and Hinds P.W. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle 4 2 (2005) 330-338
62. Chang H., Qi X., Trieu Y., et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. British Journal of Haematology 135 (2006) 486-491
63. Fonseca R., Van Wier S.A., Chng W.J., et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 20 (2006) 2034-2040
64. Hanamura I., Stewart J.P., Huang Y., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108 (2006) 1724-1732
65. Zhan F., Colla S., Wu X., et al. CKS1B, over expressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and independent mechanisms. Blood 109 (2007) 4995-5001
66. Bezieau S., Devilder M.C., Avet-Loiseau H., et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Human Mutation 18 (2001) 212-224
67. Liu P., Leong T., Quam L., et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88 (1996) 2699-2706
68. Rasmussen T., Kuehl M., Lodahl M., et al. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 105 (2005) 317-323
69. Fonseca R., Price-Troska T., Blood E., et al. Implications of N-ras and K-ras mutations in clinical outcome and the biology of multiple myeloma. Blood 102 (2003) 113
70. Chng W.J., Price-Troska T., Gonzalez-Paz N., et al. Clinical significance of TP53 mutation in myeloma. Leukemia 21 (2007) 582-584
71. Corradini P., Inghirami G., Astolfi M., et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8 (1994) 758-767
72. Neri A., Baldini L., Trecca D., et al. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81 (1993) 128-135
73. Preudhomme C., Facon T., Zandecki M., et al. Rare occurrence of P53 gene mutations in multiple myeloma. British Journal Haematology 81 (1992) 440-443
74. Drach J., Ackermann J., Fritz E., et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92 (1998) 802-809
75. Xiong W., Zhan F., Huang Y., et al. TP53 gene expression, correlated with 17p13 deletion, is a significant and independent adverse prognostic factor in multiple myeloma treated with high-dose therapy and auto-transplants. ASH Annual Meeting Abstracts 108 (2006) 3394
76. Annunziata C.M., Davis R.E., Demchenko Y., et al. Frequent engagement of the classical and alternate NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12 (2007) 115-130
77. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the non canonical NF-KappaB pathway in multiple myeloma. Cancer Cell 12 (2007) 131-144
78. Dib A., Barlogie B., Shaughnessy Jr. J.D., et al. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 109 (2007) 1337-1338
79. Gonzalez-Paz N., Chng W.J., McClure R.F., et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109 (2007) 1228-1232
80. Dilworth D., Liu L., Stewart A.K., et al. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood 95 (2000) 1869-1871
81. Dib A., Peterson T.R., Raducha-Grace L., et al. Paradoxical expression of INK4 c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Division 1 (2006) 23
82. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine 349 (2003) 2483-2494
83. Carrasco D.R., Tonon G., Huang Y., et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9 (2006) 313-325
84. Chng W.J., Santana-Davila R., Van Wier S.A., et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 20 (2006) 807-813
85. Stewart A.K., and Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. Journal of Clinical Oncology 23 (2005) 6339-6344
86. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. Journal of Clinical Oncology 23 (2005) 3412-3420
87. Chang H., Sloan S., Li D., et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology 125 (2004) 64-68
88. Winkler J.M., Greipp P., and Fonseca R. t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients. British Journal of Haematology 120 (2003) 170-171
89. Moreau P., Facon T., Leleu X., et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100 (2002) 1579-1583
90. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106 (2005) 2837-2840
91. Jaksic W., Trudel S., Chang H., et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. Journal of Clinical Oncology 23 (2005) 7069-7073
92. Chang H., Trieu Y., Qi X., et al. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leukemia Research 31 (2007) 779-782
93. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108 (2006) 2165-2172
94. Paterson J.L., Li Z., Wen X.Y., et al. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. British Journal of Haematology 124 (2004) 595-603
95. Trudel S., Ely S., Farooqi Y., et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103 (2004) 3521-3528
96. Trudel S., Li Z.H., Wei E., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105 (2005) 2941-2948
97. Trudel S., Stewart A.K., Rom E., et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107 (2006) 4039-4046
98. Chang H., Qi X.Y., and Stewart A.K. t(11;14) does not predict long-term survival in myeloma. Leukemia 19 (2005) 1078-1079
99. Chng W.J., Mulligan G., Bryant B., et al. Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events. Blood 109 (2007) 3610-3611
100. Gutierrez N.C., Castellanos M.V., Martin M.L., et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21 (2007) 143-150
101. Chang H., Qi C., Yi Q.L., et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105 (2005) 358-360
102. Calasanz M.J., Cigudosa J.C., Odero M.D., et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. British Journal of Haematology 98 (1997) 418-425
103. Fassas A.B., Spencer T., Sawyer J., et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. British Journal of Haematology 118 (2002) 1041-1047
104. Smadja N.V., Bastard C., Brigaudeau C., et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98 (2001) 2229-2238
105. Stewart A.K., Bergsagel P.L., Greipp P.R., et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 21 (2007) 529-534
106. Chng W.J., Kumar S., Vanwier S., et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Research 67 (2007) 2982-2989
107. Shaughnessy Jr. J.D., Zhan F., Burington B.E., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109 (2006) 2276-2284
108. Dispenzieri A., Rajkumar S.V., Gertz M.A., et al. Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clinic Proceedings 82 (2007) 323-341